What is the role of autologous (HCT) in the treatment of acute myeloid leukemia (AML)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Alternatively, autologous HCT can be given after (typically) one or two cycles of consolidation therapy. Allogeneic HCT should be reserved for patients who relapse. Other patients who are considered low risk for relapse and in whom a non-transplant approach could be considered include those with isolated NPM1 or biallelic CEBPA mutations.

Most other patients have less than a 50% chance of cure with consolidation chemotherapy and should thus be considered for allogeneic HCT. Newer techniques for patients without sibling or unrelated donors (cord blood and haploidentical transplants) have increased the percentage of patients who have an appropriate donor and are thus eligible for such an approach.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!